| Autor: |
Upendo L. Mseka, Jonathan Mandolo, Kenneth Nyoni, Oscar Divala, Dzinkambani Kambalame, Daniel Mapemba, Moses Kamzati, Innocent Chibwe, Marc Y.R. Henrion, Kingsley Manda, Deus Thindwa, Memory Mvula, Bright Odala, Raphael Kamng'ona, Nelson Dzinza, Khuzwayo C. Jere, Nicholas Feasey, Antonia Ho, Abena S. Amoah, Melita Gordon, Todd D. Swarthout, Amelia Crampin, Robert S. Heyderman, Matthew Kagoli, Evelyn Chitsa-Banda, Collins Mitambo, John Phuka, Benson Chilima, Watipaso Kasambara, Kondwani C. Jambo, Annie Chauma-Mwale |
| Rok vydání: |
2022 |
| Předmět: |
|
| Popis: |
BackgroundThe B.1.1.529 (Omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in the fourth COVID-19 pandemic wave across the southern African region, including Malawi. The seroprevalence of SARS-CoV-2 antibodies and their association with epidemiological trends of hospitalisations and deaths are needed to aid locally relevant public health policy decisions.MethodsWe conducted a population-based serosurvey from December 27, 2021 to January 17, 2022, in 7 districts across Malawi to determine the seroprevalence of SARS-CoV-2 antibodies. Primary sampling units (PSU) were selected using probability proportionate to the number of households based on the 2018 national census, followed by second-stage sampling units that were selected from listed households. A random systematic sample of households was selected from each PSU within the 7 districts. Serum samples were tested for antibodies against SARS-CoV-2 receptor binding domain using WANTAI SARS-CoV-2 Receptor Binding Domain total antibody commercial enzyme-linked immunosorbent assay (ELISA). We also evaluated COVID-19 epidemiologic trends in Malawi, including cases, hospitalizations and deaths from April 1, 2021 through April 30, 2022, collected using the routine national COVID-19 reporting system.ResultsSerum samples were analysed from 4619 participants (57% female; 65% aged 14 to 50 years), of whom 1018 (22%) had received a COVID-19 vaccine. The overall assay-adjusted seroprevalence was 86.3% (95% confidence interval (CI), 85.1% to 87.5%). Seroprevalence was lowest among children ConclusionWe report reduction in proportion of hospitalisations and deaths from SARS-CoV-2 infections during the Omicron variant dominated wave in Malawi, in the context of high SARS-CoV-2 seroprevalence but low COVID-19 vaccination coverage. These findings suggest that COVID-19 vaccination policy in high seroprevalence settings may need to be amended from mass campaigns to targeted vaccination of at-risk populations. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
